Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
iPSirius, a French biotechnology company that originated from INSERM and Paris Saclay University, has set its ambition on developing active cancer immunotherapy products. Their focus lies in utilizing induced pluripotent stem cell (iPSC) technology. iPSirius successfully developed its first therapeutic product known as IPVAC 1.0, with the objective of priming the patient's own immune system against a wide range of cancer targets.
Our vision is to improve prognosis of cancer patients by bringing transformational and valued therapies addressing metastasis and treatment resistance. We are currently in the planning phase for our FIH trial for IPVAC 1.0 which will be conducted in the UK.
Chief Scientific Officer
Chief Operating Officer
Chief Financial Officer
Copyright © 2024 Ipsirius - All Rights Reserved.
Powered by GoDaddy